← All trials
NCT04495088
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2020
- Primary completion
- Aug 31, 2030
- Completion date
- Aug 31, 2030
- First posted
- Jul 31, 2020
- Last posted
- Nov 12, 2020
- Enrollment
- 818
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of MannheimLead sponsor
- Deutsche Krebshilfe e.V.Collaborator
- University of MannheimSponsor investigator
- University of MannheimOverall official - principal investigator
- IKF Klinische Krebsforschung GmbH am Krankenhaus NordwestCollaborator
- German Rectal Cancer Study GroupCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.